Drug development and the FDA's critical path initiative

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 1, 2007, Pages 129-133

  Woosley, R L ^a,b   Cossman, J ^a,b  

^a CRITICAL PATH INSTITUTE   (United States)

^b Critical Path Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUORODEOXYGLUCOSE; ROFECOXIB; WARFARIN;

BIOINFORMATICS; BIOLOGICAL WARFARE; BLEEDING; CANCER; CANCER CHEMOTHERAPY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG METABOLISM; DRUG SAFETY; EMBOLISM; EVOLUTION; FOOD AND DRUG ADMINISTRATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; HEALTH CARE COST; HEALTH ECONOMICS; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFLAMMATION; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROKE;

BIOMEDICAL RESEARCH; CLINICAL TRIALS; DRUG INDUSTRY; HUMANS; INTERINSTITUTIONAL RELATIONS; PHARMACOLOGY, CLINICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33845976645     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100014     Document Type: Review

References (28)

1. DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health. Econ. 22, 151-185 (2003).
2. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
3. Mervis, J. Productivity counts - but the definition is key. Science 309, 726 (2005).
4. Veit, M. New strategies for drug development. Berl. Munch. Tierarztl. Wochenschr. 117, 276-287 (2004).
5. D'Andrea, G. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
6. Kirchheiner, J. & Brockmoller, J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1-16 (2005).
7. Badagnani, I. et al. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 318, 521-529 (2006).
8. Hung, S.I. et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genom. 16, 297-306 (2006).
9. Desta, Z., Soukhova, N., Morocho, A.M. & Flockhart, D.A. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. J. Pharmacol. Exp. Ther. 298, 508-520 (2001).
10. International Conference on Harmonisation. Guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice Fed. Regist. 70, 61134-61135 (2005).
11. O'Hara, E.D. & Wathen, J.E. Syncope, seizure, or surprise? A teenager's school trip gone awry: case report of torsades de pointes and a review of long QT syndrome. Pediatr. Emerg. Care 22, 435-438 (2006).
12. Hughes, M.D., Daniels, M.J., Fischl, M.A., Kim, S. & Schooley, R.T. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 12, 1823-1832 (1998).
13. Qadri, S.S. et al. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann. Thorac. Surg. 79, 990-995 (2005).
14. Food and Drug Administration. Innovation or stagnation: challenges and opportunity on the critical path to new medical products, http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html (2004).
15. Food and Drug Administration. Critical Path Opportunity List, http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_list.pdf (16 March 2004).
16. Food and Drug Administration. Critical Path Opportunity Report, http://www.fda.gov/oc/initiatives/criticalpath/projectsummary/consortium.html (2006).
17. The Critical Path Institute. www.C-Path.org (1 January 2006).
18. FDA Alliance. www.rarediseases.org/files/FDAAllianceLaunch.ppt (1 January 2006).
19. www.FDAcoalition.org.
20. Food and Drug Administration. Cardiovascular Biomarker Collaboration, http://www.fda.gov/oc/initiatives/criticalpath/biomarker.html (1 June 2006).
21. Hamby, L., Weeks, W.B. & Malikowski, C. Complications of warfarin therapy: causes, costs, and the role of the anticoagulation clinic. Eff. Clin. Pract. 3, 179-184 (2000).
22. Food and Drug Administration. Predictive Safety Test Consortium, http://www.fda.gov/oc/initiatives/criticalpath/projectsummary/consortium.html (16 March 2006).
23. National Cancer Institute. Early Detection Research Network, http://www3.cancer.gov/initiatives/early.html (2006).
24. Food and Drug Administration. ECG Warehouse, http://www.fda.gov/cder/ meeting/aECG/default.htm (2006).
25. European Commission. Innovative Medicines Initiative, http://ec.europa.eu/research/fp6/pdf/innovative_medicines_sra_final_draft_en. pdf#search=%22Innovative%20Medicines%20Initiative%22 (1 July 2006).
26. Irwin, D.A. & Klenow, P.J. Sematech: purpose and performance. Proc. Natl. Acad. Sci. USA 93, 12739-12742 (1996).
27. Cablelabs. CableLabs, http://www.cablelabs.com/about/ (2006).
28. Sadler, G., Chappas, W. & Pierce, D.E. Evaluation of e-beam, gamma- and X-ray treatment on the chemistry and safety of polymers used with pre-packaged irradiated foods: a review. Food Addit. Contam. 18, 475-501 (2001).